Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
HBIO

HBIO - Harvard Bioscience Inc Stock Price, Fair Value and News

$0.57-0.02 (-3.39%)
Market Closed

41/100

HBIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

41/100

HBIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.56

Target 3M

$0.58

Target 6M

$0.58

HBIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HBIO Price Action

Last 7 days

-3.4%

Last 30 days

-13.6%

Last 90 days

-9.5%

Trailing 12 Months

-66.7%

HBIO RSI Chart

HBIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HBIO Valuation

Market Cap

25.4M

Price/Earnings (Trailing)

-0.47

Price/Sales (Trailing)

0.29

EV/EBITDA

-0.38

Price/Free Cashflow

3.42

HBIO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.56

Target 3M

$0.58

Target 6M

$0.58

HBIO Fundamentals

HBIO Revenue

Revenue (TTM)

87.4M

Rev. Growth (Yr)

-6.28%

Rev. Growth (Qtr)

0.69%

HBIO Earnings

Earnings (TTM)

-53.8M

Earnings Growth (Yr)

74.36%

Earnings Growth (Qtr)

46.06%

HBIO Profitability

EBT Margin

-61.34%

Return on Equity

-382.68%

Return on Assets

-69.03%

Free Cashflow Yield

29.28%

HBIO Investor Care

Shares Dilution (1Y)

2.21%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202591.4M88.8M87.4M0
2024106.8M101.1M97.7M94.1M
2023114.5M114.1M112.5M112.3M
2022120.7M120.7M118.0M113.3M
2021105.3M111.2M116.8M118.9M
2020111.7M105.5M102.1M102.1M
2019122.2M120.3M119.1M116.2M
201886.1M98.6M108.6M120.8M
201795.6M88.5M82.2M77.4M
2016109.9M107.2M106.5M104.5M
2015108.5M110.4M110.7M108.7M
2014105.0M105.8M106.2M108.7M
2013108.9M106.5M105.6M105.2M
2012110.9M112.2M112.0M111.2M
2011108.2M109.4M109.4M108.9M
2010000108.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Harvard Bioscience Inc

HBIO
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. The company was founded in 1901 and is based in Holliston, Massachusetts.
 CEO
 WEBSITEharvardbioscience.com
 SECTORHealthcare
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES436

Harvard Bioscience Inc Frequently Asked Questions

HBIO is the stock ticker symbol of Harvard Bioscience Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Harvard Bioscience Inc is 25.41 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check HBIO's fair value in chart for subscribers.

The fair value guage provides a quick view whether HBIO is over valued or under valued. Whether Harvard Bioscience Inc is cheap or expensive depends on the assumptions which impact Harvard Bioscience Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HBIO.

As of Wed Jan 28 2026, HBIO's PE ratio (Price to Earnings) is -0.47 and Price to Sales (PS) ratio is 0.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HBIO PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Harvard Bioscience Inc has provided -0.152 (multiply by 100 for percentage) rate of return.